Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 May;23(5):223-8.
doi: 10.1007/s10815-006-9036-2. Epub 2006 Jun 20.

Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol

Kyono Koichi  1 , Nakajo Yukiko, Kumagai Shima, Sasaki Sachiko
Affiliations
Randomized Controlled Trial

Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol

Kyono Koichi et al. J Assist Reprod Genet. 2006 May.

Abstract

Purpose: To examine the efficacy of low-dose hCG using a GnRH antagonist protocol.

Methods: Prospective randomized study was performed at the Kyono Ladies Clinic. One hundred ninety-two women (<40 -years old, <3 previous cycles) were randomly assigned to GnRH agonist (buserelin) long protocol (LP, n = 66), GnRH antagonist (cetrorelix) with no low-dose hCG protocol (NhCGP, n = 63), or GnRH antagonist with low-dose hCG protocol (hCGP, n = 63).

Results: The hCGP was associated with reduced total amounts of FSH, increased oocyte maturation rate, high-quality day 3 embryos rate, and number of frozen embryos. Ovarian hyperstimulation syndrome (OHSS) tended to be lower in the GnRH antagonist protocol. Pregnancy and implantation rates did not differ significantly between study groups.

Conclusions: Daily low-dose hCG supplementation in the late follicular phase could improve the outcome in FSH based-GnRH antagonist protocol. This protocol, however, does require further modifications, including determination of the optimal doses for hCG and gonadotropin pretreatment.

PubMed Disclaimer

References

    1. Alvano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with hMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000;15:526–531. doi: 10.1093/humrep/15.3.526. - DOI - PubMed
    1. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta analysis. Arch Gynecol Obstet. 2001;265:175–182. doi: 10.1007/s00404-001-0267-2. - DOI - PubMed
    1. Al-Inary H, Aboulghar H. GnRH antagonist in assisted reproduction: A Cochran review. Hum Reprod. 2002;17:874–885. doi: 10.1093/humrep/17.4.874. - DOI - PubMed
    1. Zeleznik AJ, Hillier SG. The role of gonadotropins in the selection of the preovulatory follicle. Clin Obstet Gynecol. 1984;27:927–940. doi: 10.1097/00003081-198412000-00014. - DOI - PubMed
    1. Filicori M, Cognigni GE, Taraborrelli D, Spettoli D, Ciampaglia W, de Fatis CT, Pocognoli P. Luteinizing Hormone Activity Supplementation Enhances Follicle-Stimulating Hormone Efficacy and Improves Ovulation Induction Outcome. J Clin Endocrinol Metab. 1999;84:2659–2663. doi: 10.1210/jc.84.8.2659. - DOI - PubMed

Publication types

MeSH terms